Five providers built something most practices never attempt: an integrated delivery model with in-house specialty pharmacy and a growing infusion suite. The clinical outcomes were strong. The margins were real. But after three failed attempts to sell, time was running out. A fourth failure would have meant a distressed process, destroying value for the founders and fragmenting care for thousands of patients.

Integrated specialty practices are among the most undervalued assets in healthcare M&A. Clinical delivery, pharmacy economics, and infusion reimbursement each attract different buyers who think about value differently. Most advisors would have simplified the story to fit a standard process. That simplification would have cost the founders millions.

We did the opposite. We showed buyers this wasn't three separate businesses. It was one, and the whole was worth more than the parts. We found margin improvement inside the infusion operations that changed the deal economics for buyers. We went beyond the usual list of physician group acquirers and built a broader buyer field, including health systems and specialty platforms that saw the asset for what it actually was. One early front-runner dropped out over regulatory concerns. We kept the process competitive, brought in new qualified buyers, and managed the deal through closing on the founders' timeline.

Closed at a 33% premium above the buyer's initial target price, preserving integrated care for the patient population the founders spent decades building.

If your business doesn't fit the standard playbook, that's usually a sign of value that hasn't been captured yet.